Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
79.56B
Market cap79.56B
Price-Earnings ratio
15.98
Price-Earnings ratio15.98
Dividend yield
0.55%
Dividend yield0.55%
Average volume
854.77K
Average volume854.77K
High today
$740.06
High today$740.06
Low today
$693.61
Low today$693.61
Open price
$700.00
Open price$700.00
Volume
1.45M
Volume1.45M
52 Week high
$821.11
52 Week high$821.11
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $739.99, with a market capitalization of 79.56B. The stock trades at a price-to-earnings (P/E) ratio of 15.98 and offers a dividend yield of 0.55%.

On 2026-07-31, Regeneron(REGN) stock moved within a range of $693.61 to $740.06. With shares now at $739.99, the stock is trading +6.7% above its intraday low and -0.0% below the session's peak.

Trading activity shows a volume of 1.45M, compared to an average daily volume of 854.77K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

REGN News

Nasdaq 8h
Regeneron Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Regeneron Q2 2026 Earnings Call Transcript
TipRanks 9h
Regeneron Earnings Call Highlights Dupixent-Driven Surge

Regeneron Pharmaceuticals ((REGN)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing...

Benzinga 14h
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6% to 5.154 billion euros, above 5 billion euros per quarter for the first t...

Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
32.3%
Sell
0%

More REGN News

The Wall Street Journal 21h
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
TipRanks 2d
Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

TipRanks 3d
Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks tied to a Phas...

Seeking Alpha 3d
Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst

Kiniksa Pharmaceuticals (KNSA) added nearly 50% on Tuesday after posting another quarterly beat and guidance boost with its financials, thanks mainly to Arcalys...

Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst
Simply Wall St 4d
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals

In July 2026, Telix Pharmaceuticals announced it had entered a collaboration with Regeneron Pharmaceuticals to co-develop and commercialize next-generation radi...

Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.